EXCLUSIVE: NurExone's Wholly-Owned Subsidiary Enters Into Binding MOU For Naïve Exosome Distribution in Mexico
NUREXONE BIOLOGIC INC
NUREXONE BIOLOGIC INC NRXBF | 0.00 |
The commercial terms outlined in the MOU, including territorial exclusivity, upfront exclusivity fees,
minimum purchase commitments, funded market-entry obligations, regulatory responsibilities, and
potential regional expansion rights, are intended to be incorporated into the Definitive Agreement, which
the parties intend to execute within forty-five (45) calendar days. If completed, the Definitive Agreement
will provide Exo-Top with its first structured commercial foothold for naïve MSC-derived exosome
products.
